Article Text

Persistent bone marrow depression following short-term treatment with temozolomide
  1. Kathrine Vandraas1,
  2. Geir Erland Tjønnfjord2,
  3. Tom Børge Johannesen1,
  4. Petter Brandal1
  1. 1Oslo University Hospital, Oslo, Norway
  2. 2Department of Hematology, Oslo University Hospital, Oslo, Norway
  1. Correspondence to Dr Petter Brandal, pebra{at}


Temozolomide (TMZ) is, in combination with radiotherapy (RT), the treatment of choice for glioblastoma multiforme. Although generally well tolerated, haematological side effects are observed in approximately 1–10% of patients receiving TMZ. We report a case of a patient who developed severe bone marrow failure (BMF) after only 3 weeks of concomitant TMZ. The BMF was grave with no signs of improvement for 12 months, resulting in more than 100 transfusions of blood cells.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.